Short description
Editas Medicine is a clinical-stage genome editing company that develops genomic medicines for serious diseases.
Description
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.
Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.
Last funding
Noaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Cambridge, Massachusetts, United States, North America
Founded on
January 1, 2013
Exited on
February 3, 2016
Went public on
February 3, 2016
Stock symbol
EDIT
Non-profit?
No
Acquired?
No
Employees count
251-500
Revenue range
$7890 - 12340
Sign in for full access
Investors
Cannot Access, Nopepepe, Noaccessforu, Absolutely Noaccess, Uh Ohhhh, Uh Ohhhh, Nopepepe, Nopepepe, Blurry Noaccess, Noway Youcantaccess, Nopepepe, Noaccessforu, Noaccess, Noway Youcantaccess, Cannot Access, Noway Youcantaccess, Noway Youcantaccess, Noaccess, Noaccess
Sign in for full access
Founders
David R. Liu, Feng Zhang, George Church, J. Keith Joung, Jennifer Doudna